ASX company Memphasys says that its Felix System provides the best separation technique for recovering high-quality sperm after cryopreservation.
The cell and protein separation devices company’s announcement came on the back of results of a study titled “Analysis of sperm separation protocols for isolating cryopreserved human spermatozo”’.
For the latest health news, sign up here for free Stockhead daily newsletters
It revealed that cells separated using the Felix system exhibited significantly lower levels of DNA fragmentation following cryopreservation.
The results were presented at the annual Fertility Society of Australia and New Zealand 2023 Conference, and were also published in the medical journal Reproduction and Fertility.
To maximise successful conception and minimise the risk of genetic defects from IVF treatment, sperm is usually separated from the cryopreservation medium prior to clinical use.
The most common separation techniques currently used are density gradient centrifugation (DGC), and swim-up.
According to the study, Felix offers significant advantages over those techniques.
MORE FROM STOCKHEAD: Anti-cancer stock’s step forward | ‘Shroom boom’ on horizon| May ASX biotech winners
Chemist Warehouse signs Sigma
Sigma Healthcare (ASX:SIG) surged 22 per cent after announcing it had signed a binding deal with Chemist Warehouse for the supply of both Pharmaceutical Benefits Scheme (PBS) medicines and Fast-Moving-Consumer-Goods (FMCG) product for five years, starting on July 1, 2024.
Sigma is the incumbent supplier for FMCG product to Chemist Warehouse, and those sales represent about 29 per cent of Sigma’s net sales revenue.
Sigma’s gain today seems to be at the expense of pharmaceutical distributor, EBOS Group (ASX:EBO).
EBOS fell 15 per cent after being informed by Chemist Warehouse that it intended to pursue alternative wholesale supply arrangements, and that its contract would not be renewed beyond the expiry date of June 30, 2024.
Visit Stockhead, where ASX small caps are big deals
Anatara wants to proceed to Stage 2
Trial preliminary data readout of Anatara Lifesciences’ (ASX:ANR) GaRP Irritable Bowel Syndrome (IBS) trial supports continuation of the trial.
Anatara says statistical analysis of the first 31 participants has encouraged the company to progress from Stage 1 to Stage 2 of the GaRP-IBS trial.
This comes as after a review of the preliminary data by DSMB (the Data Safety Monitoring Board), which said that it was satisfied with the results, noting the small data set.
The DSMB also said there were no safety concerns across the participant groups.
If the trial is successful, the company believes the high prevalence of digestive disorders requiring relief including irritable bowel syndrome (IBS), will present a significant market opportunity.
An interim analysis report is anticipated late Q3 of this year.
This content first appeared on stockhead.com.au
SUBSCRIBE
Get the latest Stockhead news delivered free to your inbox. Click here